JP2011523550A5 - - Google Patents

Download PDF

Info

Publication number
JP2011523550A5
JP2011523550A5 JP2011508949A JP2011508949A JP2011523550A5 JP 2011523550 A5 JP2011523550 A5 JP 2011523550A5 JP 2011508949 A JP2011508949 A JP 2011508949A JP 2011508949 A JP2011508949 A JP 2011508949A JP 2011523550 A5 JP2011523550 A5 JP 2011523550A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
acid sequences
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011508949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523550A (ja
JP6034023B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/056026 external-priority patent/WO2009138519A1/en
Publication of JP2011523550A publication Critical patent/JP2011523550A/ja
Publication of JP2011523550A5 publication Critical patent/JP2011523550A5/ja
Application granted granted Critical
Publication of JP6034023B2 publication Critical patent/JP6034023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011508949A 2008-05-16 2009-05-18 Cxcr4及び他のgpcrに指向性を有するアミノ酸配列及びそれを含む化合物 Active JP6034023B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5384708P 2008-05-16 2008-05-16
US61/053,847 2008-05-16
US10214208P 2008-10-02 2008-10-02
US61/102,142 2008-10-02
PCT/EP2009/056026 WO2009138519A1 (en) 2008-05-16 2009-05-18 AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME

Publications (3)

Publication Number Publication Date
JP2011523550A JP2011523550A (ja) 2011-08-18
JP2011523550A5 true JP2011523550A5 (https=) 2013-06-13
JP6034023B2 JP6034023B2 (ja) 2016-11-30

Family

ID=40974643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508949A Active JP6034023B2 (ja) 2008-05-16 2009-05-18 Cxcr4及び他のgpcrに指向性を有するアミノ酸配列及びそれを含む化合物

Country Status (14)

Country Link
US (1) US9212226B2 (https=)
EP (1) EP2285833B1 (https=)
JP (1) JP6034023B2 (https=)
KR (1) KR20110020825A (https=)
CN (1) CN102099378B (https=)
AU (1) AU2009248049B2 (https=)
BR (1) BRPI0911984A2 (https=)
CA (1) CA2724208C (https=)
IL (1) IL209176A0 (https=)
MX (1) MX2010012518A (https=)
NZ (1) NZ589036A (https=)
RU (1) RU2010151725A (https=)
WO (1) WO2009138519A1 (https=)
ZA (1) ZA201008180B (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2352764B1 (en) * 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
EP3470425A3 (en) 2008-12-19 2019-07-17 Ablynx N.V. Immunoglobulins against cell-associatd antigens such as p2x7
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011083141A2 (en) * 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EA202092589A3 (ru) * 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
FR2970781B1 (fr) * 2011-01-25 2013-02-08 Centre Nat Rech Scient Procede de fabrication d'un support d'analyse et utilisation pour la detection de toxines
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104053667B (zh) * 2011-06-21 2017-09-15 非营利性组织佛兰芒综合大学生物技术研究所 针对gpcr:g蛋白复合物的结合结构域及来自其的用途
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP2944653A1 (en) 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
DK2974737T3 (da) 2011-06-23 2026-01-19 Ablynx Nv Fremgangsmåder til forudsigelse, påvisning og reduktion af en specifik proteininterferens i assays, der involverer variable immunglobulin-enkeltdomæner
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
KR20160098514A (ko) * 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
CN102993295A (zh) * 2012-09-29 2013-03-27 张文彬 双峰驼褪黑素受体、编码基因及其获取方法
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2015026884A1 (en) * 2013-08-21 2015-02-26 Boehringer Ingelheim International Gmbh Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
KR20250099289A (ko) * 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
ES2900852T3 (es) 2014-05-16 2022-03-18 Ablynx Nv Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento
PL3248986T3 (pl) 2014-05-16 2022-05-16 Ablynx Nv Domeny zmienne immunoglobuliny
US10273305B2 (en) 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
NO2768984T3 (https=) 2015-11-12 2018-06-09
CN115925919A (zh) 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
CN120535622A (zh) 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
US10544222B2 (en) 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
JP7540877B2 (ja) 2016-02-12 2024-08-27 アブリンクス エン.ヴェー. 免疫グロブリン単一可変ドメインの生成方法
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
MX2018016413A (es) 2016-06-23 2019-05-09 Ablynx Nv Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina.
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
SG10202108972RA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
HRP20241501T1 (hr) 2017-01-17 2025-01-03 Ablynx Nv Poboljšana veziva albumina u serumu
EP3602056A1 (en) 2017-03-31 2020-02-05 Ablynx N.V. Improved immunogenicity assays
CN111741752A (zh) 2017-12-19 2020-10-02 Gpcr治疗公司 Gpcr异聚体抑制剂及其用途
LT3638698T (lt) 2018-01-26 2021-04-12 Regeneron Pharmaceuticals, Inc. Antikūnai prieš tmprss2 ir antigeną surišantys fragmentai
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
MX2022009476A (es) 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
JP2023527352A (ja) 2020-05-26 2023-06-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片
CN111596070B (zh) * 2020-06-10 2023-05-12 宁波大学 一种三疣梭子蟹原肌球蛋白过敏检测试剂的应用
WO2021254979A1 (en) * 2020-06-16 2021-12-23 Ludwig-Maximilians-Universität München Chemokine-selective cxcr4 ectodomain-derived (poly)peptide
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023155902A1 (en) 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
MA71603A (fr) 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
KR20250094703A (ko) 2022-10-25 2025-06-25 아블린쓰 엔.브이. 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
CN115960269B (zh) * 2023-01-30 2026-04-03 上海甲贝医药科技有限公司 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン.ヴェー. 新生児型fc受容体に結合するポリペプチド
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
CN121511255A (zh) 2023-05-17 2026-02-10 奥德赛治疗股份有限公司 经修饰的单结构域抗体
IL325291A (en) 2023-06-29 2026-02-01 Odyssey Therapeutics Inc Anti-TRAILR2 antigen-binding proteins and their uses
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
AU2024329349A1 (en) 2023-08-23 2026-04-09 Sanofi Ctla-4-based lysosomal degraders and uses thereof
US20250129145A1 (en) 2023-09-22 2025-04-24 Ablynx N.V. Bi- and multivalent albumin binders
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
CN120818528B (zh) * 2025-07-14 2026-02-10 贵州大学 萝卜RsBBX9基因在调控花青素合成中的应用及方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
EP1068357B2 (en) * 1998-03-30 2014-12-10 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US7018812B2 (en) * 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1456410A2 (en) * 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
WO2003066830A2 (en) * 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
ATE554390T1 (de) 2003-08-20 2012-05-15 Ucb Pharma Sa Verfahren zur gewinnung von antikörpern
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2006116319A2 (en) 2005-04-21 2006-11-02 Chemocentryx, Inc. Reagents that bind ccx-ckr2
EP1934259A2 (en) 2005-10-11 2008-06-25 Ablynx N.V. Nanobodies and polypeptides against egfr and igf-ir
WO2007055823A2 (en) 2005-10-28 2007-05-18 Multispan, Inc. Gpcr expressing cell lines and antibodies
DE602006018057D1 (de) 2005-11-10 2010-12-16 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2008074839A2 (en) * 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
EP3470425A3 (en) 2008-12-19 2019-07-17 Ablynx N.V. Immunoglobulins against cell-associatd antigens such as p2x7
WO2010141986A1 (en) 2009-06-09 2010-12-16 Mabdesign Pty Ltd Novel antibodies and uses therefor
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US20140228223A1 (en) 2010-05-10 2014-08-14 Andreas Gnirke High throughput paired-end sequencing of large-insert clone libraries
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域

Similar Documents

Publication Publication Date Title
JP2011523550A5 (https=)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
RU2010151725A (ru) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2020500510A5 (https=)
JP4294596B2 (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
CN111606993B (zh) 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
JP2012518425A5 (https=)
JP2014518883A5 (https=)
JP2011521662A5 (https=)
JP2018537421A5 (https=)
JP6587609B2 (ja) 強皮症治療のための抗ccl2及び抗loxl2併用療法
JP2010511388A5 (https=)
CN111201246A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN109311983B (zh) 人源化抗clever-1抗体及其用途
JP2019506839A5 (https=)
JP2021534727A (ja) Sftsvに結合可能なナノ抗体及びその使用
JP2012524524A5 (https=)
JP2013511996A5 (https=)
WO2013178783A1 (en) P2x7 receptor antagonists and agonists
JP2017529870A5 (https=)
CN116075524A (zh) 转铁蛋白受体结合蛋白
Aoki et al. Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor
JP2024023268A5 (https=)
JP2017536821A5 (https=)